Moreover, MALAT1 inhibits ubiquitin-proteasomal degradation of the N-HER2 by affecting the binding of deubiquitinase USP8 and N-HER2, thereby promoting N-HER2 accumulation and trastuzumab resistance in HER2-positive breast cancer. This evidence concerns the gene USP8 and breast carcinoma.